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Abstract
Background: Streptococcus tigurinus was recently described as a new streptococcal species within the viridans
group streptococci (VGS). The objectives of the present work were to analyse the clinical and microbiological
characteristics of S. tigurinus isolated from patients with bacteraemias, to determine the prevalence of S. tigurinus
among VGS endocarditis in Spain, and to compare the clinical characteristics and outcomes of endocarditis caused by
S. tigurinus and other VGS.
Methods: Retrospective nationwide study, performed between 2008 and 2016 in 9 Spanish hospitals from 7 different
provinces comprising 237 cases of infective endocarditis. Streptococcal isolates were identified by sequencing
fragments of their 16S rRNA, sodA and groEL genes. Clinical data of patients with streptococcal endocarditis
were prospectively collected according to a pre-established protocol.
Results: Patients with endocarditis represented 7/9 (77.8%) and 26/86 (30.2%) of the bacteraemias caused by
S. tigurinus and other VGS, respectively (p < 0.001), in two of the hospital participants. Among patients with
streptococcal endocarditis, 12 different Streptococcus species were recognized being S. oralis, S. tigurinus and
S. mitis the three more common. No relevant statistical differences were observed in the clinical characteristics
and outcomes of endocarditis caused by the different VGS species.
Conclusions: In this multicenter study performed in Spain, S. tigurinus showed a higher predilection for the
endocardial endothelium as compared to other VGS. However, clinical characteristics and outcomes of endocarditis
caused by S. tigurinus did not significantly differ from endocarditis caused by other oral streptococci.
Keywords: Streptococcus Viridans, Infective endocarditis, Multicentre studies, Epidemiologic surveillance, Antibiotic
resistance
Background
Streptococcus tigurinus was firstly described as a new
streptococcal species in 2012 based on DNA hybridization
analysis and 16S rRNA sequencing, being genetically very
similar to Streptococcus oralis [1]. In fact, in 2016, and
based on whole-genome sequencing, it was proposed to
classify S. tigurinus as a Streptococcus oralis subspecies [2].
S. tigurinus, as other mitis group streptococci has been
found as a commensal of the human oral cavity although
since its initial description it has been also docu-
mented as a causative agent of infective endocarditis
(IE) and other infections as meningitis, spondylodisci-
tis, osteomyelitis, prosthetic infections, etc. [1, 3–7].
The objective of the present study was to establish the
clinical and microbiological characteristics of S. tigurinus
isolated from patients with bacteraemias, to determine the
prevalence of S. tigurinus among the cases of viridans
group streptococci (VGS) endocarditis in Spain, and to
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compare the outcomes of IE caused by S. tigurinus and by
other VGS.
Methods
S. tigurinus prevalence study
To study the relevance of finding S. tigurinus in a blood cul-
ture, all VGS isolated from blood cultures collected between
2008 and 2016 in two hospitals from Barcelona and San Se-
bastian, two cities from the north of Spain separated more
than 500 km apart, were classified by phenotypic methods
and all S. oralis were further identified by gene sequencing.
S. tigurinus endocarditis study
To analyse the characteristics of IE caused by S. tigurinus, a
retrospective nationwide study, performed between 2008
and 2016 in 9 Spanish hospitals located in 7 different prov-
inces comprising 237 cases of IE was performed. Diagnosis
of IE was done according to the revised Duke diagnostic
criteria [8]. Clinical IE data were prospectively collected ac-
cording to a pre-established protocol [9]. Only cases with
definite IE diagnosis were included in the study.
Microbiological techniques
VGS isolates were identified by sequencing fragments
of their 16S rRNA, sodA and groEL genes and compar-
ing them with those available at the NCBI and LeBibi
databases [10]. A similitude of > 99% with the 3 genes
was considered for a correct species identification. All
S. tigurinus detected were genotyped by MLST accord-
ing to the established protocol at the Oral Streptococ-
cus MLST Database web page (https://pubmlst.org/
oralstrep). Antimicrobial MICs were determined by the
broth microdilution method using Iso-Sensitest Broth
(Oxoid) supplemented with lysed horse blood 5% v/v.
After incubation for 24 h at 35 °C, susceptibility results
were read and interpreted according to CLSI guide-
lines. S. pneumoniae ATCC 49619 was used as control.
Statistical analysis
The unpaired t-test or the chi-square test (Fisher’s exact
test when appropriate) was used to compare continuous
and categorical variables, respectively. All statistical ana-
lyses were performed using the online available Graph-
Pad software (www.graphpad.com/quickcalcs/).
Ethical considerations
The project and the common case report form were ap-
proved by the national and local institutional review boards
and ethics committees (E.C. 18/07) and all patients gave
their written informed consent to participate in the study.
Results
In the present work, 169 VGS isolates were identified by
molecular methods: 95 from the prevalence study and 74
from the study of IE. The 16S rRNA gene correctly identi-
fied all of them, sodA misidentified one S. oralis isolate as
S. tigurinus and groEL misidentified 5 S. oralis isolates as
S. tigurinus (n = 2), S. cristatus (n = 2) and S. mitis (n = 1).
S. tigurinus prevalence study
Overall, 95 cases of VGS bacteraemias recorded in the
hospitals of Barcelona and San Sebastian were studied,
being 9 identified as S. tigurinus. Patients with endo-
carditis represented 7/9 (77.8%) of the S. tigurinus and
26/86 (30.2%) of the remaining VGS (p = 0.008). This
data suggests a bigger attraction of S. tigurinus for the
endocardial endothelium as compared with related
species of the VGS, a finding that has been also ob-
served in other studies [6].
S. tigurinus endocarditis study
Of the 237 IE caused by VGS recorded in the study, 74
isolates were available for further studies and were identi-
fied by phenotypic methods and by gene sequencing. In
global, 12 different Streptococcus species were recognized
being S. oralis, S. tigurinus and S. mitis the three more
common causing 37.8, 23.0 and 21.6% of IE cases respect-
ively (Table 1). All S. tigurinus had been previously identi-
fied by phenotypic methods as S. oralis and were found in
5/9 hospitals and in 4/7 provinces. All S. tigurinus were
fully susceptible to oral penicillin, amoxicillin, and cefotax-
ime except one isolate that had a penicillin MIC = 0.12mg/
L. Three isolates were tetracycline-resistant (MIC> 4mg/L)
and another three erythromycin-resistant (MIC = 2mg/L).
All S. tigurinus isolates were susceptible to clindamycin,
levofloxacin and vancomycin. A large heterogeneity of S.
tigurinus was observed by MLST, having all different ST.
Among the 17 S. tigurinus isolates, there were only two ST
Table 1 Species of viridans group streptococci causing infective
endocarditis in Spain, 2008–2016
Species n %
S. oralis 28 37.8%
S. tigurinus 17 23.0%
S. mitis 16 21.6%
S. parasanguinis 3 4.1%
S. sanguinis 2 2.7%
S. pneumoniae 2 2.7%
S. infantis 1 1.4%
S. salivarius 1 1.4%
S. infantarius 1 1.4%
S. gordonii 1 1.4%
S. anginosus 1 1.4%
S. alactolyticus 1 1.4%
Total 74
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Table 2 Clinical data of patients with infective endocarditis caused by S. mitis, S. oralis, S. tigurinus and other viridans group
streptococci, Spain, 2008–2016
S. mitis (n = 16) S. oralis (n = 28) S. tigurinus (n = 17) Other VGS (n = 13)
Demographics
Age in years: average ± SD (range) 58.4 ± 17.5 (35–94) 60.0 ± 16.7 (32–86) 66.7 ± 17.2 (19–87) 61.2 ± 13.9 (28–80)
Female/Male 2/14 4/24 6/11 5/8
Underlying conditions
Diabetes mellitus 2 2 0 0
Renal insufficiency 0 1 2 1
Pulmonary disease 3 2 3 1
Neoplasm 2 2 3 1
HIV infection 0 3 0 1
Risk factors
Previous infective endocarditis 2 5 2 1
Heart failure 1 4 4 2
Atrial fibrillation 3 4 2 1
Site of acquisition
Nosocomial 0 0 0 0
Community -acquired 15 27 16 12
Health care-related 1 1 1 1
Symptoms at admission
Affected valve
Aortic 6 14 7 7
Mitral 6 9 6 2
Aortic + mitral 2 3 2 2
Tricuspid 1 0 0 0
Tricuspid + mitral 0 0 0 1
Aortic + tricuspid + mitral 0 1 0 0
Pulmonary 1 0 0 0
Ductus arteriosus 0 0 0 1
Not determined 0 1 2 0
Presentation
Fever> 38 °C 16 23 13/16a 11
Splinter hemorrhages 1 0 0 2
Osler nodes 0 0 0 1
Janeway lesions 1 0 0 1
New murmur 3 15 5/16 8
Worsening of old murmur 0 4/24 1/15 0
Protein C reactive: average ± SD (range) 74.2 ± 41.5 (13–168) 55.7 ± 45.6 (1–138) 52.3 ± 96.4 (3–356) 40.8 ± 42.7 (3–101)
Elevated Rheumatoid factor 0/2 4/11 1/4 2/4
Vegetations
Not found 6 6 6 4
Aortic 4 10 6 5
Mitral 3 7 3 1
Tricuspid 1 0 0 0
Aortic + mitral 1 5 2 2
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previously defined in the MLST database, ST30 and ST65,
both previously identified as S. oralis from patients with
gingivitis. Comparing IE caused by S. tigurinus and other
VGS, patients´ average age was higher for S. tigurinus
endocarditis, without statistical significance (p = 0.179 com-
pared to S. mitis) (Table 2). No relevant statistical differ-
ences were observed in the clinical characteristics of IE
caused by the different VGS species. Left heart valves were
more frequently affected in S. tigurinus IE as well as in
other streptococci: 45.9% mitral, 31.1% aortic, and 13.6%
both valves. Considering all VGS IE, perforation was the
most common intracardiac complication (16.2%), followed
by abscess (10.8%) and pseudoaneurysm alone (2.7%) or
with perforation (2.7%). In-hospital overall mortality in
VGS IE (10.8%) was relatively high as compared with other
studies [11]. Mortality due to S. tigurinus was quite similar
to that of S. oralis (11.3% vs 14.8%, p = 1). Surprisingly, no
mortality was recorded for any of the 16 patients with S.
mitis IE that was also the group with less patients requiring
surgical treatment. Of the patients with IE caused by
VGS, 22 were treated only with betalactams (20 with
ceftriaxone, 1 with ceftriaxone and ampicillin and 1
Table 2 Clinical data of patients with infective endocarditis caused by S. mitis, S. oralis, S. tigurinus and other viridans group
streptococci, Spain, 2008–2016 (Continued)
S. mitis (n = 16) S. oralis (n = 28) S. tigurinus (n = 17) Other VGS (n = 13)
Mitral + tricuspid 0 0 0 1
Chordae tendinae 1 0 0 0
Intracardiac complications
Perforation 2 4 3 3
Abscess 1 4 1 2
Pseudoaneurysm 0 1 0 1
Pseudoaneurysm & perforation 0 2 0 0
NC 0 1 0 2
Clinical course
Embolism 1 6/27a 5/16a 4
New heart failure 1 12/27a 5 4
Persistent bacteraemia 1 0 0 1
Surgery
Indicated 5 19/27a 9 7
Performed 5 18/27a 6 6
Criteria for surgeryb
Cardiac insufficiency 2 9 2 3
Early prosthetic IE 0 1 0 0
Late prosthetic IE 1 2 0 0
Valve insufficiency 3 10 3 4
Embolisms 0 1 0 1
Others 1 5 3 1
Outcome
Days hospital stay: average ± SD (range) 32.4 ± 19.3 (9–85) 31.0 ± 21.8 (3–106) 29.3 ± 17.9 (5–74) 29.9 ± 16.3 (6–53)
In- hospital mortality 0 4 2 2
1-year mortalityc 0/14 3/22 2/15 1/8
Recurrence 0 2 2 0
Antibiotic treatment
Beta-lactams alone 6 9 6 5
Beta-lactams + gentamicin 8 12 7 6
Other combinations 2 7 4 2
aDenominator adjusted to patients with data available
bSome patients had more than one criteria for surgery
cExcluding patents died at hospital
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with imipenem), 26 with betalactams and gentamicin,
being ceftriaxone-gentamicin the combination most
frequently used (in 10 patients ceftriaxone-gentamicin
alone and in another 8 with a third antibiotic). There
were no differences in the antibiotic treatment despite
the species identified.
Discussion
Despite the advances in imaging (echocardiography and
nuclear medicine), molecular microbiology and surgery,
IE is still today a serious disease with high morbidity and
mortality rates. In high-income countries, epidemiology of
IE is changing with an increase of elderly patients with
prosthetic valves or implantable cardiovascular devices
[11]. Also, etiologic agents causing IE seems to be chan-
ging, with an increase of staphylococcal IE and a reduction
of IE caused by VGS [11, 12]. In this Spanish multicenter
study, it was previously shown that VGS represented
27.5% cases of definitive IE [13]. In the present work it has
been shown that S. tigurinus was responsible for 20% of
these definitive IE cases caused by VGS.
S. tigurinus has been associated to IE since its first de-
scription, although it has been also described as causing
meningitis, spondylodiscitis, prosthetic infections, osteo-
myelitis, and periodontitis among others. However, in a
recent review, IE was the most commonly reported
manifestation of S. tigurinus infection [6] probably be-
cause IE has been more systematically searched for than
other kind of infections. In that review, no deaths were
documented among patients with S. tigurinus infection
except for one case of osteomyelitis. In our study, 2 pa-
tients with S. tigurinus IE died during admission with no
difference in mortality rates to IE caused by other VGS.
Besides to the oral origin of S. tigurinus infections, an
enteric source has been also postulated after the trans-
location of the pathogen from an intraabdominal dis-
order [14]. However we considered that in most of our
patients the origin was the oral cavity as no intraabdom-
inal condition was found in any of the patients, whether
the causative agent of the IE was S. tigurinus or another
of the VSG commonly found in the oral mucosa. The
oral origin of most VGS IE highlights the need of an ex-
quisite dental care in patients with risk for IE [15].
IE caused by S. tigurinus did not clinically differ from
IE caused by other VGS, showing a community-acquired
origin, clinical course and outcomes in general better
than bacterial IE caused by other Gram-positive bacteria
as Staphylococcus aureus or Enterococcus [11]. Despite
the wide genomic heterogeneity most isolates were fully
susceptible to commonly used antibiotics in the treatment
of IE. An endocarditis should always be suspected when a
S. tigurinus is isolated from a blood culture due to the
high prevalence of IE caused by this, otherwise com-
mensal bacteria.
Conclusion
In this multicenter study performed in Spain, S. tiguri-
nus was a common cause of IE. Clinical characteristics
and outcomes of S. tigurinus endocarditis did not differ
from endocarditis caused by other VGS. S. tigurinus
showed a high genomic heterogeneity with most isolates
susceptible in vitro to antibiotics commonly used in the
treatment of IE.
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